{"name":"Immuron","slug":"immuron","ticker":"IMRN","exchange":"NASDAQ","domain":"immuron.com","description":"Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.","hq":"Melbourne, Australia","founded":0,"employees":"7","ceo":"Steven Lydeamore","sector":"Biotech / Immunology / GI","stockPrice":1.16,"stockChange":0.27,"stockChangePercent":30.34,"marketCap":"$7M","metrics":{"revenue":5402079.3333907,"revenueGrowth":4.8,"grossMargin":63.7,"rdSpend":0,"netIncome":-3356868.7257582997,"cash":7221536.0213472,"dividendYield":0,"peRatio":-116,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"Travasol patent cliff ($1.4M at risk)","drug":"Travasol","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"IMM-124E","genericName":"IMM-124E","slug":"imm-124e","indication":"Other","status":"phase_2"},{"name":"Travelan","genericName":"Travelan","slug":"travelan","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"IMM-124E","genericName":"IMM-124E","slug":"imm-124e","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Travelan","genericName":"Travelan","slug":"travelan","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Immuron Reports FY2023 Financial Results","summary":"Immuron reported a net loss of $14.4 million for FY2023, with revenue of $1.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Immuron Enters into Agreement with US-Based Biotech Company","summary":"Immuron has entered into an agreement with a US-based biotech company to collaborate on the development of a new immunotherapy product.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-12","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-09","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-23","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-20","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-14","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-12","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-16","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-15","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-12","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-10","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-05","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-04","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"}],"patents":[{"drugName":"Travasol","drugSlug":"-travasol","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":1400000}],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Janssen Pharmaceuticals","Pfizer","Gilead Sciences"],"therapeuticFocus":["Gastrointestinal (GI) diseases","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":5264794.4550323,"revenuePeriod":"2025-06-30","revenueHistory":[{"period":"2025-06-30","value":5264794.4550323},{"period":"2024-06-30","value":3542276.57214475},{"period":"2023-06-30","value":1303883.3908607499},{"period":"2022-06-30","value":552845.17054195}],"grossProfit":3442741.85637385,"grossProfitHistory":[{"period":"2025-06-30","value":3442741.85637385},{"period":"2024-06-30","value":2410806.30184655},{"period":"2023-06-30","value":945847.12154905},{"period":"2022-06-30","value":378225.5620073}],"rdSpend":2599014.5239303997,"rdSpendHistory":[{"period":"2025-06-30","value":2599014.5239303997},{"period":"2024-06-30","value":3883722.9996701498},{"period":"2023-06-30","value":1872801.82201675},{"period":"2022-06-30","value":475193.26672225}],"sgaSpend":5683923.1310057,"operatingIncome":-3870190.74043065,"operatingIncomeHistory":[{"period":"2025-06-30","value":-3870190.74043065},{"period":"2024-06-30","value":-3768397.51732485},{"period":"2023-06-30","value":-2461180.552298},{"period":"2022-06-30","value":-2252303.30339495}],"netIncome":-3768504.4460150497,"netIncomeHistory":[{"period":"2025-06-30","value":-3768504.4460150497},{"period":"2024-06-30","value":-5011890.0404305495},{"period":"2023-06-30","value":-2735717.79691305},{"period":"2022-06-30","value":-2062173.2548520998}],"eps":-0.908,"epsHistory":[{"period":"2025-06-30","value":-0.908},{"period":"2024-06-30","value":-1.216},{"period":"2023-06-30","value":-0.664},{"period":"2022-06-30","value":-0.5}],"cash":2045029.9848449,"cashHistory":[{"period":"2025-06-30","value":2045029.9848449},{"period":"2024-06-30","value":8422306.92026225},{"period":"2023-06-30","value":12397777.626088599},{"period":"2022-06-30","value":15974480.1790397}],"totalAssets":7318721.1958983,"totalLiabilities":1488900.36953505,"totalDebt":51914.60158325,"equity":5829820.82636325,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":-140.88577425,"capexHistory":[{"period":"2024-06-30","value":-140.88577425},{"period":"2023-06-30","value":-5591.35900985},{"period":"2022-06-30","value":-7259.5910752},{"period":"2021-06-30","value":-4790.1163245}],"freeCashflow":-4433891.340501349,"dividendsPaid":0,"buybacks":null,"employees":7,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.16,"previousClose":0.89,"fiftyTwoWeekHigh":2.39,"fiftyTwoWeekLow":0.68,"fiftyTwoWeekRange":"0.677 - 2.39","fiftyDayAverage":0.81,"twoHundredDayAverage":1.31,"beta":0.41,"enterpriseValue":202969658.4068096,"forwardPE":-116,"priceToBook":1,"priceToSales":1.27,"enterpriseToRevenue":37.57,"enterpriseToEbitda":-59.27,"pegRatio":0,"ebitda":-3424271.3701241,"ebitdaMargin":-63.4,"freeCashflow":-2471598.874681,"operatingCashflow":-3393405.82570495,"totalDebt":147326.06036109998,"debtToEquity":1.6,"currentRatio":8.04,"returnOnAssets":-21.9,"returnOnEquity":-39.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":4.04,"targetHighPrice":4.04,"targetLowPrice":4.04,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0,"institutionHeldPercent":1.7,"sharesOutstanding":8166340,"floatShares":320652982,"sharesShort":19430,"shortRatio":0.57,"shortPercentOfFloat":0.2,"epsTrailing":-0.54,"epsForward":-0.01,"revenuePerShare":1.16,"bookValue":1.16,"officers":[{"age":57,"name":"Mr. Steven George Lydeamore CPA, M.B.A.","title":"Chief Executive Officer"},{"age":64,"name":"Dr. Jerry  Kanellos Ph.D.","title":"Chief Operating Officer"},{"age":51,"name":"Mr. Flavio  Palumbo","title":"Chief Commercial Officer"},{"age":null,"name":"Mr. Aaron  Laurita","title":"Chief Financial Officer"},{"age":null,"name":"Mr. David  Lyon","title":"Head of Marketing"},{"age":null,"name":"Ms. Olga  Smejkalova","title":"Company Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.immuron.com.au","phone":"61 3 9824 5254"}}